Walter & Keenan Wealth Management LLC IN ADV Sells 27,314 Shares of Pfizer Inc. (NYSE:PFE)

Walter & Keenan Wealth Management LLC IN ADV lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 29.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,954 shares of the biopharmaceutical company’s stock after selling 27,314 shares during the period. Walter & Keenan Wealth Management LLC IN ADV’s holdings in Pfizer were worth $1,697,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Quilter Plc boosted its stake in Pfizer by 10.5% in the 4th quarter. Quilter Plc now owns 1,660,527 shares of the biopharmaceutical company’s stock valued at $44,054,000 after purchasing an additional 157,298 shares during the period. Opal Wealth Advisors LLC lifted its holdings in shares of Pfizer by 11.9% during the fourth quarter. Opal Wealth Advisors LLC now owns 10,061 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 1,072 shares in the last quarter. Wingate Wealth Advisors Inc. bought a new stake in shares of Pfizer in the fourth quarter valued at about $53,000. Angeles Wealth Management LLC grew its stake in shares of Pfizer by 18.2% in the fourth quarter. Angeles Wealth Management LLC now owns 18,679 shares of the biopharmaceutical company’s stock valued at $496,000 after acquiring an additional 2,882 shares in the last quarter. Finally, V2 Financial group LLC increased its position in Pfizer by 20.6% during the fourth quarter. V2 Financial group LLC now owns 29,671 shares of the biopharmaceutical company’s stock worth $787,000 after acquiring an additional 5,071 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.76 on Monday. The firm has a 50 day simple moving average of $26.28 and a 200 day simple moving average of $27.73. The company has a market cap of $145.96 billion, a price-to-earnings ratio of 18.27, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the business posted $0.10 EPS. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.68%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 121.99%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on PFE shares. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Guggenheim cut their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Sanford C. Bernstein assumed coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.